Navigation Links
EUSA Pharma Completes Establishment of Commercial Infrastructure With Appointment of President for Europe and International Region
Date:3/8/2010

n aggressive organic growth and further product in-licensing and acquisition."

About EUSA Pharma

EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight marketed products, including Caphosol(R) for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high dose chemotherapy, Erwinase(R) and Kidrolase(R) for the treatment of acute lymphoblastic leukemia, Collatamp(R) G, a surgical implant impregnated with the antibiotic gentamicin, ProstaScint(R) for imaging the extent and spread of prostate cancer and Quadramet(R) for the treatment of pain in patients whose cancer has spread to the bones. EUSA also has several products in late-stage development.

Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, TVM Capital, NeoMed and NovaQuest. Since its foundation, the company has raised over $300 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Limited, the French biopharmaceutical company OPi
'/>"/>

SOURCE EUSA Pharma Inc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
2. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009
3. Tianyin Pharmaceutical Co., Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing on March 9
4. PDL BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Provides First Quarter 2010 Revenue Guidance
5. ClearTrial Launches New Service to Bring Speed and Accuracy in Clinical Trial Planning Within Reach of Smaller Biopharma Companies
6. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
7. APT Pharmaceuticals Completes Enrollment in Phase III for Inhaled Cyclosporine
8. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Fourth Quarter and Full Year Financial Results
9. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer
10. The MedZilla Report for February 2010 - Health Care Growth Slows; Big Pharma May Cut Thousands as Sales Landscape Changes
11. Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... | RBJ today announces the firm brokered a long-term lease ... leading biopharmaceutical company, at Two Ledgemont Center in ... , president, and Brian Cohen , senior vice president, ... at 95 Hayden Ave. Photo - http://photos.prnewswire.com/prnh/20150122/170765 ...
(Date:1/22/2015)... 21, 2015 Cambridge Semantics, the leading provider ... announced that 2014 was a record-breaking year across the board ... the Anzo Smart Data Platform and our Smart Data solutions, ... from diverse data which led to record growth for the ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Crystal Diagnostics (CDx) ... that it has received AOAC-PTM Certifications for the six non-O157 ... and O145; collectively referred to as STEC or the “Big-6”) ... colony forming unit (cfu) per 325 g of raw ground ...
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently was ... Pre-Conference seminar on probiotics in San Diego, CA. , ... conference for health care professionals. This year’s pre-conference seminar was ... in health. Dr. Leyer spoke about the emerging topics and ...
Breaking Biology Technology:Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Cambridge Semantics Announces Record Results for 2014 2Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2
... Inc. (Nasdaq: NVAX ) a clinical-stage vaccine company, ... be presenting at the Cowen and Company 29th Annual Healthcare ... at the Boston Marriott Copley Place in Boston, MA. Dr. ... and development progress. A link to the live presentation ...
... YORK, March 13 Jina Ventures is pleased ... Swiss Pharma Contract (SPC) by leading contract research ... Jina Ventures was the exclusive financial advisor ... facilities and services of Basel, Switzerland area-based SPC."We are thrilled ...
... PRINCETON, N.J., March 13 Covance Inc. (NYSE: ... is expanding its clinical pharmacology footprint in Europe ... 50-bed clinical research company based in Basel, Switzerland."Our ... that can help them make decisions faster is ...
Cached Biology Technology:Jina Ventures Advises Swiss Pharma Contract on Strategic Sale to Covance Inc 2Covance Increases Early Clinical Footprint in Europe with Acquisition of Swiss-Based Early Clinical Development Site 2
(Date:12/22/2014)... Dec. 22, 2014 Research and Markets ... the "The Global Watermarking and Fingerprinting Markets" ... http://photos.prnewswire.com/prnh/20130307/600769 This insight ... watermarking and fingerprinting markets. Watermarking aims to control ...
(Date:12/19/2014)... 18, 2014   LaunchKey , the first decentralized mobile ... Internet of Things era, today announced the close of ... was led by Metamorphic Ventures with participation from ENIAC ... and others.  LaunchKey has raised $4 million to date, ...
(Date:12/17/2014)... Dec. 16, 2014 Research and Markets ( ... "Global Chemical Sensor Market 2015-2019" report to their ... One major trend upcoming in this market is ... Chemical sensors help in recording of patient data for ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... Inc., a privately-held company dedicated to maternal and fetal ... nd Annual Meeting of the American Society of ... San Francisco, California. (Logo: http://photos.prnewswire.com/prnh/20120425/SF94380LOGO ) ... access to a blood test that is safe, early ...
... to make cordite, the explosive propellant that replaced gunpowder ... new use in the production of advanced biofuels. With ... U.S. Department of Energy (DOE),s Lawrence Berkeley National Laboratory ... butanol and ethanol from lignocellulosic biomass could be selectively ...
... is a natural battery a chamber filled with ions ... today,s issue of the journal Nature Biotechnology , a ... Infirmary (MEEI) and the Harvard-MIT Division of Health Sciences and ... could power implantable electronic devices without impairing hearing. The ...
Cached Biology News:Verinata Health Announces New Findings At The American Society Of Human Genetics 2More bang for the biofuel buck 2More bang for the biofuel buck 3More bang for the biofuel buck 4Medical devices powered by the ear itself 2Medical devices powered by the ear itself 3
Recombinant Mouse MMP-9, CF...
Viral CMV UL146/vCXC1 Biotinylated Affinity Purified PAb...
Cyan Standard is 7-hydroxy-4-trifluoromethylcoumarin...
... High Sensitivity Freezing Point Osmometer for 10 L sample. Ideal for small volume applications, including pediatric, ... Ready to run in less than 3 minutes after turn-on. ... ... ...
Biology Products: